SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-063737
Filing Date
2023-03-08
Accepted
2023-03-08 07:06:02
Documents
14
Period of Report
2023-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d478193d8k.htm   iXBRL 8-K 24998
2 EX-99.1 d478193dex991.htm EX-99.1 77301
6 GRAPHIC g478193g27y04.jpg GRAPHIC 5252
  Complete submission text file 0001193125-23-063737.txt   250776

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20230308.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20230308_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20230308_pre.xml EX-101.PRE 11286
8 EXTRACTED XBRL INSTANCE DOCUMENT d478193d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 23714848
SIC: 8071 Services-Medical Laboratories